Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lexeo Therapeutics, Inc. (LXEO) Cash & Equivalents (2022 - 2023)

Lexeo Therapeutics' Cash & Equivalents history spans 2 years, with the latest figure at $35.4 million for Q3 2023.

  • For Q3 2023, Cash & Equivalents fell 62.35% year-over-year to $35.4 million; the TTM value through Sep 2023 reached $35.4 million, down 62.35%, while the annual FY2022 figure was $77.3 million, N/A changed from the prior year.
  • Cash & Equivalents for Q3 2023 was $35.4 million at Lexeo Therapeutics, down from $77.3 million in the prior quarter.
  • Across five years, Cash & Equivalents topped out at $94.2 million in Q3 2022 and bottomed at $35.4 million in Q3 2023.